StockData
Parabilis Medicines, Inc. logo

Parabilis Medicines, Inc. (PBLS) company profile

PBLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$28.25−0.20 (-0.70%)

Close on Nov 17, 2026Market cap $3.49BP/E –Yield –

About Parabilis Medicines

Pharmaceutical Preparations, SIC 2834

Parabilis Medicines, Inc. is listed on Nasdaq under the ticker PBLS, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.

Company profile

Company

Legal name
Parabilis Medicines, Inc.
Headquarters
Cambridge, MA
Address
30 Acorn Park Drive, 6th Floor 02140
Phone
(617) 945-9510
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
PBLS
Exchange
Nasdaq
IPO date
Jun 10, 2026
Shares outstanding
124M, Aug 10, 2026
Filer category
<br>Emerging growth company
SEC CIK
1657677
CUSIP
698955101
ISIN
US6989551014
FIGI
BBG00KXR8FS7
Share class FIGI
BBG00KXR8FT6
EIN
47-4505725

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mathai MammenPresident & CEO, Director–
Teresa JurgensenGeneral Counsel–
Helen Huei-in HoSee Remarks–
Mohammed Fawzi BenzaghouChief Medical Officer–
Rohin MhatreSee Remarks–
Thomas Rodolpho KotarakosChief Financial Officer–
Craig TendlerDirector–
Capital Healthcare Fund LP RADirector–
Rajeev M. ShahDirector–
RA Capital Nexus Fund III, L.P.Director6,556,740
Peter KolchinskyDirector–
Ra Capital Management, L.P.Director26,529,686
Alan SebulskyDirector25,935
Edward M. FitzgeraldDirector14,688
Alexis BorisyDirector105,414
Richard KlausnerDirector–
Barbara WeberDirector–
Jake SimsonDirector–
Krishna YeshwantDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 10, 2026
Offer price
$20.00
Securities offered
33,500,000
Gross proceeds
$670.00M
Exchange
Nasdaq
First trading day
Jun 10, 2026
First-day close
$31.60+58.0%
Lock-up ends (est.)
Dec 7, 2026

“The initial public offering price per share is $20.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 10, 2026IPOInitial public offering priced (424B4 prospectus)
Jun 5, 2026ListingRegistration of securities on an exchange (Form 8-A)
Dec 2, 2022Name changeName changed from FOG PHARMACEUTICALS, INC. to Parabilis Medicines, Inc.

See a number that looks wrong?